Vivus Reports Results of Qsymia in Pilot Clinical Study for Patients with Laparoscopic Sleeve Gastrectomy Surgery

Shots:

• The pilot clinical study involves assessing of Qsymia (phentermine and topiramate ER caps) in 25 patients with a BMI of 50+ who were planning to undergo LSG vs patients undergoing surgery alone without anti-obesity medication (AOM)
• The clinical study results: @24mos. BMI (33.8 kg/m² vs 42 kg/m²); average wt. loss (28.1 kg vs 12.3 kg); @2yrs. post LSG (11.2% vs -18.2%); BMI<40 @24 post LSG (61.5% vs. 47.5%); wt. loss more than twice as much weight during preoperative treatment
• Qsymia is an anti-obesity therapy indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults BMI of 30 kg/m²+ or 27 kg/m²+ with at least one weight-related medical condition such as high BP, T2D or high cholesterol

Click here to­ read full press release/ article | Ref: Vivus | Image: Vivus